Eurycomanone / testos Cancer Research Results

EU, Eurycomanone: Click to Expand ⟱

Features:

Eurycomanone — Eurycomanone is a highly oxygenated quassinoid diterpenoid from Eurycoma longifolia Jack, commonly known as tongkat ali or longjack. It is a small-molecule plant secondary metabolite and should be classified as a natural-product quassinoid, not as an essential oil constituent. It is best indexed separately from crude Eurycoma longifolia extract because isolated eurycomanone has specific anticancer mechanisms, while commercial tongkat ali extracts have variable composition and separate androgenic/supplement safety issues.

Primary mechanisms (ranked):

Induction of intrinsic apoptosis through p53 activation, ↑ Bax, ↓ Bcl-2, and downstream caspase activation.
Suppression of cancer-cell proliferation, clonogenic growth, and cell-cycle progression in multiple in-vitro cancer models.
Autophagy inhibition in colon cancer through mTOR activation, ↓ LC3-II, and reduced autophagosome formation.
Anti-invasive and anti-EMT activity in NSCLC models through inhibition of TGF-β1-linked Smad and non-Smad signaling, including Akt-linked effects and ↓ MMP-2 secretion.
Anti-angiogenic signaling in colon cancer models, mainly as a preclinical tumor-support pathway effect.
Context-dependent modulation of steroidogenic pathways, including aromatase and phosphodiesterase inhibition; this is pharmacologically relevant but not a core anticancer mechanism.

Bioavailability / PK relevance: Oral exposure is plausible but constrained by formulation, extract matrix, and rapid disposition; pure eurycomanone and standardized Eurycoma extracts are not interchangeable for PK interpretation. Cancer evidence is mostly based on isolated compound exposure in cell culture, so achievable systemic concentrations remain a major translation constraint.

In-vitro vs systemic exposure relevance: Several anticancer studies use micromolar or microgram-per-mL concentrations that may exceed typical nutraceutical oral exposure. Non-toxic anti-invasive NSCLC work used sub-cytotoxic micromolar doses, but clinical relevance remains uncertain without cancer PK/PD data. This is concentration-driven pharmacology, not field-based or trigger-based therapy.

Clinical evidence status: Preclinical only for cancer. No cancer RCTs, no oncology deployment, and no regulatory approval as an anticancer drug. Human studies and supplement safety data relate mainly to Eurycoma longifolia extracts for male-health indications, not isolated eurycomanone for cancer.

Eurycomanone Mechanistic Profile

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	p53 Bax Bcl-2 mitochondrial apoptosis	↑ p53, ↑ Bax, ↓ Bcl-2, ↑ apoptosis	Relative sparing reported in some non-malignant comparator cells, but not fully established	G	Intrinsic apoptotic killing	Most central anticancer mechanism; reported in HepG2, cervical carcinoma, breast cancer, and leukemia-related models.
2	Caspase 9 caspase 3 apoptosis execution	↑ caspase-dependent apoptosis	Model-dependent selectivity	G	Execution-phase apoptosis	Fits mitochondrial apoptosis pattern; strongest when paired with p53 Bax Bcl-2 findings.
3	Proliferation and cell-cycle control	↓ proliferation, ↓ colony formation, cell-cycle arrest (model-dependent)	Less defined	G	Growth suppression	Broad preclinical anticancer signal, but potency and selectivity vary by cell line and assay.
4	mTOR autophagy inhibition	↑ mTOR signaling, ↓ LC3-II, ↓ GFP-LC3 puncta, ↓ protective autophagy	Not well characterized	R/G	Reduced survival autophagy	Colon cancer data suggest autophagy supports survival under eurycomanone stress; autophagy inhibition strengthens growth inhibition.
5	TGF-β1 EMT Smad signaling	↓ EMT, ↓ migration, ↓ invasion, ↑ E-cadherin or ↓ N-cadherin depending on cell line	Not established	G	Anti-invasive effect	Relevant to metastatic NSCLC behavior; effects differ between A549 and Calu-1 cells.
6	Akt non-Smad EMT signaling	↓ Akt-linked EMT signaling (context-dependent)	Not established	R/G	Migration and invasion suppression	Secondary to TGF-β1 anti-EMT mechanism; therapeutic leverage is anti-metastatic rather than direct cytotoxicity.
7	MMP-2 extracellular matrix invasion	↓ MMP-2 secretion, ↓ Matrigel invasion	Not established	G	Reduced matrix invasion	Supports anti-metastatic classification in NSCLC models.
8	Angiogenesis support signaling	↓ angiogenesis-associated activity in colon cancer models	Normal endothelial-cell selectivity not fully defined	G	Reduced tumor-support signaling	Preclinical pathway; not sufficient alone to classify as a validated anti-angiogenic therapy.
9	A549 tumor marker proteins	↓ prohibitin, ↓ annexin 1, ↓ ERp28 reported	Not established	G	Proteomic tumor phenotype modulation	Useful as supporting mechanistic evidence in lung cancer, but less central than apoptosis or EMT inhibition.
10	ROS NRF2 oxidative stress	Insufficient direct eurycomanone cancer evidence for core ranking	Eurycoma extract shows antioxidant effects in non-cancer models	G	Context-dependent stress modulation	ROS or NRF2 is NOT a primary cancer mechanism.
11	Steroidogenesis aromatase phosphodiesterase	Potential hormone-context relevance, not a direct anticancer axis	↑ androgenic or fertility-related signaling in reproductive models	G	Endocrine pharmacology	Important safety and interpretation constraint, especially for hormone-sensitive disease contexts.
12	Clinical Translation Constraint	In-vitro potency may not match oral systemic exposure	Supplement safety is extract-dependent; liver injury is a possible rare concern	G	Limits clinical use	Main constraints are oral PK, extract variability, lack of cancer trials, dose ceiling, possible hepatotoxicity signal, and uncertain normal-cell therapeutic window.

TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr

testos, testosterone: Click to Expand ⟱

Source:

Type:

Hormone therapy — slows cancer growth by lowering testosterone levels in the body.
"shaking up prostate cancer with high-dose testosterone makes it more vulnerable to other treatments."
testosterone-levels-in-men-with-prostate-cancer" >There is a higher incidence of prostate cancer among men with low testosterone.

Prostate cancer is highly sensitive to androgenic stimulation. Testosterone—and more potently, its derivative dihydrotestosterone (DHT)—binds to the androgen receptor (AR) in prostate cells, which can drive the growth and survival of both normal and malignant cells.

Castration-Resistant Prostate Cancer (CRPC):

Even after testosterone levels are medically reduced, some prostate cancers continue to thrive by adapting their AR pathway. CRPC often signals a transition to a more aggressive, treatment-resistant state.

Scientific Papers found: Click to Expand⟱

6582-

EU,

Eurycoma longifolia (Jack) Improves Serum Total Testosterone in Men: A Systematic Review and Meta-Analysis of Clinical Trials

Review,

Nor,

*testos↑,

6584-

EU,

Eurycoma longifolia: an overview on the pharmacological properties for the treatment of common cancer

Review,

Var,

*AntiAge↑, *Inflam↓, *antiOx↑, TumCD↑, Bcl-2↓, cl‑Casp7↑, cl‑PARP↑, BAX↑, P53↑, tumCV↓, selectivity↑, *testos↑, *PSA∅,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:

Drug Metabolism & Resistance ⓘ

selectivity↑, 1,
Total Targets: 8

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

antiOx↑, 1,

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1, PSA∅, 1,

Hormonal & Nuclear Receptors ⓘ

testos↑, 2,

Clinical Biomarkers ⓘ

PSA∅, 1,

Functional Outcomes ⓘ

AntiAge↑, 1,
Total Targets: 6

Scientific Paper Hit Count for: testos, testosterone

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:415  Target#:458  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid